HOME >> BIOLOGY >> NEWS
Potential therapy reported for children, adults with end-stage liver disease

A Johns Hopkins Children's Center scientist reports success in animal studies in preventing a cascade of brain pathology that appears to both cause and signal the final and fatal stages of acute and chronic liver disease in children and adults. The findings ("Hyperammonemic Encepalopathy") appear in the May issue of Medicine.

In the review article, pediatric biochemical geneticist Saul Brusilow, M.D., writes that the chemical methionine sulfoximine (MSO) appears to prevent the brain swelling (encephalopathy) in patients with acute liver failure. It is the swelling, he believes, that causes pressure on the patient's brain, which leads to coma and ultimately death.

MSO is known to prevent the formation of glutamine, a by-product of high ammonia levels in the blood (hyperammonemia). Patients with advanced liver disease develop hyperammonemia as the failing liver can no longer process ammonia, a natural by-product in humans. "Interrupt glutamine formation and the swelling that follows and we might be able to prevent brain damage and death," says Brusilow.

Experimental evidence suggests that glutamine forms in one type of brain cell, the astrocyte. As glutamine accumulates, water also accumulates, causing the astrocyte to swell. It is this swelling, Brusilow theorizes, that puts pressure on the brain in acute liver failure, and interrupts the normal functions of the astrocyte; patients may then lapse into unconsciousness and death. Patients with chronic liver failure demonstrate the consequences of astrocyte swelling by exhibiting behavioral changes rather than brain swelling.

In their animal studies, Brusilow, emeritus professor of Pediatrics at Johns Hopkins, and his colleagues Richard Traystman, Ph.D., and Raymond Koehler, Ph.D., both in the Department of Anesthesiology and Critical Care Medicine, pretreated rats with MSO, then induced hyperammonemia. Compared to rats not pretreated, the test animals showed no swelling in either their a
'"/>

Contact: Wendy Mullins
wmullins@jhmi.edu
410-223-1741
Johns Hopkins Medical Institutions
13-May-2002


Page: 1 2

Related biology news :

1. Potential for enhanced sequestration of carbon in soils supports evaluations
2. Potential blood test for colon cancer risk
3. Potential new treatment for Gaucher disease developed by scientists at Scripps Research Institute
4. Potential cause of arthritis discovered
5. Potential of regenerative medicine explored
6. Potential allergy vaccine boosts hope for sufferers
7. Potential of tailoring drugs to genetic makeup confirmed--but challenges remain
8. Potential new anthrax therapy discovered
9. Potential gene therapy carriers created that mimic viruses, without the risk
10. New Class Of Synthetic Capsules That Mimic Biological Cells Has Wide Array Of Potential Uses
11. Role Of Protein Linked To Colon Cancer Identified, Offering Potential Target For Therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/2/2020)... ... March 02, 2020 , ... Nominations are now being accepted for the ... Security Industry Association (SIA) and SecureIDNews and co-presented with sponsors ... . The recipients of this year’s Women in Biometrics Awards will be honored at ...
(Date:2/28/2020)... ... February 28, 2020 , ... Meridian Clinical Research , a leading investigative ... award for Best Clinical Trial Site. Meridian is also the largest member of ... Network award. These nominations were the result of two voting rounds, and winners will ...
(Date:2/28/2020)... ... February 27, 2020 , ... An upcoming episode ... solutions for maladies, such as Inflammatory Bowel Disease (IBD), specifically Crohn’s Disease (Crohn’s), ... focus on a novel platform developed by Deka Biosciences, Inc. (Deka Biosciences), that ...
Breaking Biology News(10 mins):
(Date:3/13/2020)... ... 12, 2020 , ... Today, DuPont Nutrition & Biosciences (DuPont) ... a pioneer in the field of microbiome science, which focuses on microbes that ... health, based at University College Cork and Teagasc Moorepark. , Representatives from both ...
(Date:3/10/2020)... HOUSTON, Tex. (PRWEB) , ... ... ... Solutions, a full-service cold chain biopharmaceutical engineering firm, is pleased to ... primary focus is on combination medical device qualification and validation in the ...
(Date:3/4/2020)... ... March 04, 2020 , ... This month, Cognosante will make ... The company will showcase both expanded and emerging offerings that align with the HIMSS ... is designed to be comprehensive, timely, and engaging. From Interoperability and HIE ...
(Date:3/2/2020)... ... ... McBee, Moore and Vanik IP, LLC (MMV IP) has been ranked 12th ... , According to statistics compiled by Harrity Anaytics, MMV IP was listed as the ... during 2019. Technology center 1600 at the US Patent Office (“USPTO”) specializes in the ...
Breaking Biology Technology:
Cached News: